Introduction
============

Cancer is one of the most important health problems of mankind. The 5-year relative survival rate for all cancers in Americans and Chinese is \~69% and 37%, respectively.[@b1-ott-9-5771],[@b2-ott-9-5771] Thus, the researches for prognostic indicators of cancer survival have important clinical values. Nowadays, numerous cancer prognostic factors have been discovered,[@b3-ott-9-5771]--[@b5-ott-9-5771] and the prognostic values of microRNAs also have been proved by many studies.[@b6-ott-9-5771]--[@b8-ott-9-5771]

MicroRNAs are a kind of small noncoding RNA molecule in biology, containing \~22 nucleotides, that function in posttranscriptional regulation of gene expression and RNA silencing.[@b9-ott-9-5771],[@b10-ott-9-5771] MicroRNAs regulate tumorigenesis and cancer progression, also as gatekeepers of apoptosis for tumors.[@b11-ott-9-5771],[@b12-ott-9-5771] Through different mechanisms, microRNA can perform the role of a tumor promoter[@b13-ott-9-5771],[@b14-ott-9-5771] or cancer suppressor factor.[@b15-ott-9-5771]--[@b17-ott-9-5771] Meanwhile, microRNA in cancers can also be up-[@b18-ott-9-5771],[@b19-ott-9-5771] or downregulated.[@b20-ott-9-5771],[@b21-ott-9-5771]

MicroRNA-133a (miR-133a) plays an important role in cancer development and progression. Studies showed that miR-133a is a tumor suppressor.[@b22-ott-9-5771],[@b23-ott-9-5771] Consequently, decreased expression of miR-133a in cancer patients correlates with poor survival and prognosis.[@b24-ott-9-5771]--[@b27-ott-9-5771] However, the results from some studies find that lower expression of miR-133a functioned as a favorable outcome factor.[@b28-ott-9-5771],[@b29-ott-9-5771] Thus, as these results so far seem to be controversial, it is still not enough to draw a conclusion for the prognostic value of decreased miR-133a.

As a fact, most researches assessing the implications of miR-133a expression in cancer were limited by the small sample sizes. Therefore, we performed this meta-analysis and expected to handle the inconsistencies of previous studies.

Materials and methods
=====================

Search strategy
---------------

The searches were performed by two reviewers (Jian Xiao and Yong Zou) independently. Articles were searched on PubMed, Web of Science, and Embase (updated to February 19, 2016) with language restriction of English. The search terms of keywords and their combination were as the following: "microRNA-133a OR mir-133a OR microRNA133a OR mir133a OR 133a" AND "survival OR prognosis OR prognostic" AND "cancer OR tumor OR tumour OR neoplasm OR neoplasma OR cancers OR tumors OR tumours OR neoplasms OR neoplasmas OR carcinoma OR carcinomas". A manual search for the references of relevant articles was also performed to find out other potential studies. Any differences were resolved by discussion.

Inclusion and exclusion criteria
--------------------------------

Eligible studies for this meta-analysis met the following inclusion criteria: 1) evaluated the correlation between miR-133a expression and overall survival (OS) of patients with any cancer types; 2) full-text was available; and 3) reported hazard ratios (HRs) with 95% confidence intervals (CIs) or sufficient data to evaluate the HRs and 95% CIs. The exclusion criteria were the following: 1) nonhuman researches, meta-analysis, and duplicated studies; 2) letters, case reports, comments, and meeting abstracts; and 3) neither reported HR and 95% CI nor parameters (such as survival curve) to indirectly obtain them.

Data extraction
---------------

Two investigators (Jian Xiao and Xiaoxiao Lu) reviewed the eligible articles independently. Any disagreements were brought to a conclusion by discussion. Information is collected from the following items: first author; year of publication, region, type of cancer, stage, cases, sex, median age, follow-up, test method, tissue preservation, cutoff value, patients with follow-up, high/low expression cases of miR-133a, outcome, analysis of variance, HR, and 95% CI as well as source of HR. No specific information represented unreported content of any items above. If both univariate and multivariate analyses of OS results were performed, HRs and 95% CIs were extracted preferentially from the multivariate analyses. When Kaplan--Meier curves were the only available information, OS data were gained from the previously stated method.[@b30-ott-9-5771]

Statistical analysis
--------------------

STATA 12.0 software (StataCorp LP, College Station, TX, USA) was used to conduct all the statistical analyses. According to the cutoff values provided by the original published articles, miR-133a was defined as a high (or upregulated) and low (or downregulated) group. The HRs and their corresponding 95% CIs were performed to calculate the pooled HRs and 95% CIs. If HR \>1 and its 95% CI did not overlap with 1, patients with decreased expression of miR-133a indicated a poor prognosis. The heterogeneity of combined HRs was figured out using Cochran's *Q* test and Higgins' *I*-squared statistic. If there was a result of *P*\<0.05 or *I*^2^\>50%, heterogeneity was defined, and then the random-effects model was applied. If not, a fixed-effects model was conducted. Subgroup analysis and meta-regression were further adopted to explore the possible explanations for heterogeneity. Sensitivity analysis, by successively omitting each study, was performed to assess the stability of the results. Publication bias was evaluated by Begg's and Egger's test. *P*\<0.05 was considered statistically significant, and all the *P*-values were two-tailed.

Results
=======

Eligible studies and characteristics
------------------------------------

The initial search identified 59 potentially relevant records. After the duplicates were removed, 28 records were preserved. By further reviewing, 21 studies were determined to be of acceptable relevance and assessed for eligibility. However, eleven of them were excluded due to without OS data. Finally, ten studies met the eligible criteria and were included in this meta-analysis.[@b24-ott-9-5771]--[@b29-ott-9-5771],[@b31-ott-9-5771]--[@b34-ott-9-5771] The flow diagram on the selection process is shown in [Figure 1](#f1-ott-9-5771){ref-type="fig"}.

In total, 877 patients with follow-up data from four regions (People's Republic of China, Iran, Japan, and Taiwan) were included in this study. Solid cancers included in our meta-analysis derived from five cancer types: osteosarcoma,[@b24-ott-9-5771],[@b28-ott-9-5771],[@b33-ott-9-5771] non-small-cell lung cancer (NSCLC),[@b26-ott-9-5771],[@b34-ott-9-5771] esophageal cancer[@b32-ott-9-5771] (or esophageal squamous cell carcinoma[@b31-ott-9-5771]), colorectal cancer,[@b25-ott-9-5771],[@b29-ott-9-5771] and pancreatic cancer.[@b27-ott-9-5771] All of the miR-133a expression was tested by quantitative real-time polymerase chain reaction. The main characteristics of ten eligible studies are summarized in [Tables 1](#t1-ott-9-5771){ref-type="table"} and [2](#t2-ott-9-5771){ref-type="table"}.

OS is associated with decreased miR-133a expression
---------------------------------------------------

The pooled HR showed that decreased expression of miR-133a was significantly associated with unfavorable OS in patients with solid cancers (HR =1.62, 95% CI: 1.16--2.24, *P*=0.004) ([Figure 2](#f2-ott-9-5771){ref-type="fig"}). However, obvious heterogeneity (*I*^2^=59.3%, *P*=0.008) was discovered by using a random-effects model. Therefore, sensitivity analysis was performed to assess the stability of the results by successively omitting each study. Results showed the pooled HRs did not vary substantially by excluding any individual study, indicating a better stability of this meta-analysis ([Figure 3](#f3-ott-9-5771){ref-type="fig"}). Furthermore, a meta-regression was conducted to investigate the potential responsible factors for the heterogeneity. It found that none of these factors, including region, cancer type, cases (as well as the number of patients with follow-up data), maximum follow-up month, tissue preservation, cutoff value, and analysis of variance was contributing to the heterogeneity significance.

Subgroup analyses were performed according to the following categories: cancer type, region, tissue preservation, and analysis of variance. As the results shown in [Figure 4](#f4-ott-9-5771){ref-type="fig"} and [Table 3](#t3-ott-9-5771){ref-type="table"}, compared with the total pooled HR, decreased miR-133a exhibited a stronger correlation with poor OS in the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20--2.51, *P*=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41--2.53, *P*\<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42--3.02, *P*\<0.001). In the meantime, these three subgroups also presented relatively low heterogeneity (*I*^2^=52.2%, *P*=0.079; *I*^2^=40.5%, *P*=0.121; and *I*^2^=0.0%, *P*=0.443, respectively) ([Table 3](#t3-ott-9-5771){ref-type="table"}). However, subgroups, such as osteosarcoma, NSCLC, formalin-fixed and paraffin-embedded (FFPE) tissue preservation, and univariate analysis, showed no statistically significant association between decreased miR-133a and OS outcome ([Table 3](#t3-ott-9-5771){ref-type="table"}).

Publication bias assessment
---------------------------

As shown in [Figure 5](#f5-ott-9-5771){ref-type="fig"}, we performed Begg's funnel plot and Egger's test to evaluate the publication bias for all articles in this meta-analysis. The *P*-values of Begg's and Egger's test were 0.37 and 0.15, respectively, suggesting no obvious risk of publication bias.

Discussion
==========

In mammal cells, miR-133a performs many regulating functions. It regulates adipocyte browning in vivo[@b35-ott-9-5771] and modulates osteogenic differentiation of the vascular smooth muscle cells.[@b36-ott-9-5771] MiR-133a is also a biomarker for postmenopausal osteoporosis[@b37-ott-9-5771] and can predict cardiac hypertrophy in chronic hemodialysis patients.[@b38-ott-9-5771] In cancer research, miR-133a is regarded as a potential biomarker for breast cancer detection.[@b39-ott-9-5771] It inhibits the growth of cervical cancer and gastric cancer by targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor, respectively.[@b40-ott-9-5771],[@b41-ott-9-5771] Therefore, miR-133a is considered to be a tumor suppressor. Consequently, downregulated miR-133a induces cancer progression and predicts poor prognosis in cancer patients.[@b24-ott-9-5771],[@b25-ott-9-5771] However, no meta-analyses are performed so far to evaluate the prognostic value of decreased miR-133a in patients with solid cancers. So, we have done this meta-analysis.

In our meta-analysis, ten eligible articles met the inclusion criteria. The outcome of cancer patients was collected by OS data. By using a random-effects model to get the pooled HRs, the combined results indicated that decreased miR-133a expression was associated with an unfavorable prognosis in patients with solid cancers. Sensitivity analysis showed that no individual study was obviously affecting the overall result, indicating the pooled result of this meta-analysis is stable. However, due to evident heterogeneity between the included studies, we conducted further subgroup analyses regarding cancer type, region, tissue preservation, and analysis of variance. Despite osteosarcoma, NSCLC, FFPE tissue preservation, and univariate analysis subgroups showed no statistically significant correlation between decreased miR-133a and OS. While, compared with the total pooled HR, the subgroups of digestive system neoplasms, frozen tissue preservation, and multivariate analysis exhibited stronger connection between decreased miR-133a expression and OS outcome with relatively low heterogeneity. In addition, no publication bias was observed.

The results of this meta-analysis have several considerable implications. First, decreased miR-133a may be a common poor prognostic marker for solid cancers. The original researches of our meta-analysis were derived from five cancer types: osteosarcoma,[@b24-ott-9-5771],[@b28-ott-9-5771],[@b33-ott-9-5771] NSCLC,[@b26-ott-9-5771],[@b34-ott-9-5771] esophageal cancer,[@b31-ott-9-5771],[@b32-ott-9-5771] colorectal cancer,[@b25-ott-9-5771],[@b29-ott-9-5771] and pancreatic cancer.[@b27-ott-9-5771] As the pooled result from all these cancer types showed decreased miR-133a was correlated with a poor OS; thus, the conclusion can basically extend to all solid cancers.[@b42-ott-9-5771],[@b43-ott-9-5771] Second, decreased miR-133a probably is a reliable biomarker of poor survival for patients with digestive system neoplasms. Our analysis results showed that decreased miR-133a in patients with digestive system neoplasms exhibited poorer OS compared with osteosarcoma and NSCLC. However, the specific mechanism for this phenomenon needs to be explored in further research. Third, cancer tissues preserved by freezing may be more appropriate for microRNA detection than FFPE. Although studies showed consistent correlations between matched FFPE and frozen samples on the expression of microRNAs,[@b44-ott-9-5771],[@b45-ott-9-5771] the expression of a specific microRNA (eg, miR-133a) maybe is different. Unlike FFPF tissue preservation subgroup, our results indicated decreased miR-133a was obviously associated with poor prognosis in frozen tissues. It implicated that frozen tissues may reflect the expression of microRNA more actually than FFPE samples. Fourth, multivariate analysis maybe is more suitable for the researches on the correlation between microRNA expression and OS outcome in patients with cancer. The multivariate analysis subgroup in this meta-analysis exhibited stronger connection between decreased miR-133a expression and OS compared with the subgroup of univariate analysis. However, as the multivariate analysis ruled out the compounding effects from other factors, such as tumor size, stage, and nodal status,[@b24-ott-9-5771]--[@b26-ott-9-5771] the pooled results from studies conducted by multivariate analysis may be considered as more reliable.

In cancer, microRNAs act as tumor suppressors when they downregulate different proteins with oncogenic activity.[@b46-ott-9-5771] Similarly, microRNAs act as oncogenes if they downregulate genes involved in cell differentiation or as tumor suppressors.[@b46-ott-9-5771] For the ten original studies included in our meta-analysis, most of them reported that miR-133a functions as a tumor suppressor and the decreased expression of miR-133a was correlated with poor prognostic in patients with solid cancer while a few other studies reported inconsistent results,[@b28-ott-9-5771],[@b29-ott-9-5771],[@b34-ott-9-5771] indicating miR-133a maybe is a tumor promoter. We considered the reason for this paradox maybe is that miR-133a downregulated different target genes in different cancer types ([Table 4](#t4-ott-9-5771){ref-type="table"}).

Except for miR-133a, the miR-133 family also contains miR-133b. Studies found that miR-133b acts as a tumor suppressor and its expression was decreased in many types of solid cancers, such as NSCLC, bladder cancer, ovarian cancer, and gastric cancer.[@b47-ott-9-5771]--[@b50-ott-9-5771] In addition, many other studies also reported that both miR-133a and miR-133b were decreased together in solid cancer tissues.[@b31-ott-9-5771],[@b50-ott-9-5771]--[@b52-ott-9-5771] Further considering the results of our current meta-analysis, all these evidences indicate that the decreased expression of miR-133 family maybe is the reliable predictor, suggesting patients with solid cancer will have a poor prognosis.

Nevertheless, when interpreting the results of this meta-analysis, several limitations should be noticed. One of the main limitations is the limited region for the included source of cancer patients. Patient populations in this study were limited to Asia, lacking data from other regions, such as Europe, America, Oceania, and Africa. Our results need to be proved by more studies from other regions. Another limitation is that some HR data were extracted from survival curves, which may introduce bias. Thus, the present statistics seem to be less reliable than those directly obtained from published studies. If possible, pooled HRs should be performed based on directly obtained data from the published studies. In addition, all of the included studies in our meta-analysis were designed for retrospective studies, which are more possible to be published when they report positive rather than negative results. Consequently, the association between decreased miR-133a and poor OS may have been overestimated. Finally, obvious heterogeneity showed in between studies, even though we used random-effects models to calculate the pooled HRs. The heterogeneity may be attributed to the inconformity in different population characteristics, types of cancer, treatment strategies, and so on, which will likely reduce the reliability of this study and those findings similar to ours.[@b53-ott-9-5771],[@b54-ott-9-5771]

Conclusion
==========

Our meta-analysis concluded that decreased miR-133a expression is significantly associated with poor OS in patients with solid cancer. However, our results also need to be cautiously considered because of the limitations described above. Further studies related to specific cancer types and large sample sizes are required to verify the prognostic value of decreased miR-133a in various cancers.
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![Flow diagram of the selection of eligible studies.](ott-9-5771Fig1){#f1-ott-9-5771}

![Forest plot showing the association between decreased microRNA-133a and OS in patients with solid cancers (used a random-effects model).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; OS, overall survival.](ott-9-5771Fig2){#f2-ott-9-5771}

![Sensitivity analysis for this meta-analysis.\
**Abbreviation:** CI, confidence interval.](ott-9-5771Fig3){#f3-ott-9-5771}

![Forest plots showing the HRs and their corresponding CIs by cancer type subgroups (used a random-effects model).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio.](ott-9-5771Fig4){#f4-ott-9-5771}

![Egger's plot (**A**) and Begg's funnel plot (**B**) for publication bias.\
**Abbreviation:** SE, standard error.](ott-9-5771Fig5){#f5-ott-9-5771}

###### 

Main characteristics of the eligible studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               Year   Region                       Type of cancer      Stage    Cases   Sex\            Median age\     Follow-up\
                                                                                                               (male/female)   (range)         (months)
  ----------------------------------- ------ ---------------------------- ------------------- -------- ------- --------------- --------------- ------------
  Ji et al[@b33-ott-9-5771]           2013   People's Republic of China   Osteosarcoma        I--III   92      64/28           20 (7--73)      60

  Mirghasemi et al[@b24-ott-9-5771]   2015   Iran                         Osteosarcoma        I--IV    35      18/17           NSI             78

  Lan et al[@b34-ott-9-5771]          2015   People's Republic of China   NSCLC               I--IV    125     75/50           61.1 (23--90)   51

  Fujiwara et al[@b28-ott-9-5771]     2014   Japan                        Osteosarcoma        NSI      48      31/17           NSI             143

  Chen et al[@b31-ott-9-5771]         2014   People's Republic of China   ESCC                I--IV    100     69/31           50 (40--80)     50

  Akanuma et al[@b32-ott-9-5771]      2014   Japan                        Esophageal cancer   I--IV    140     121/19          NSI             120

  Wan et al[@b29-ott-9-5771]          2014   People's Republic of China   Colorectal cancer   I--IV    125     73/51           71.8 (29--95)   65

  Wang et al[@b26-ott-9-5771]         2014   Taiwan                       NSCLC               I--III   112     88/24           NSI             52

  Qin et al[@b27-ott-9-5771]          2013   People's Republic of China   Pancreatic cancer   I--II    95      40/55           NSI             58

  Wang et al[@b25-ott-9-5771]         2014   People's Republic of China   Colorectal cancer   I--III   169     96/73           NSI             77
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; NSI, no specific information; NSCLC, non-small-cell lung cancer.

###### 

Further relevant data of all identified studies

  Study                               Year   Test method   Tissue preservation   Cutoff value                                        Patients with follow-up   High expression/low expression   Outcome   Analysis of variance   HR and 95% CI       Source of HR
  ----------------------------------- ------ ------------- --------------------- --------------------------------------------------- ------------------------- -------------------------------- --------- ---------------------- ------------------- ----------------
  Ji et al[@b33-ott-9-5771]           2013   qRT-PCR       Frozen                Lower than the median value                         92                        46/46                            OS        Univariate             1.87 (1.12--3.31)   Survival curve
  Mirghasemi et al[@b24-ott-9-5771]   2015   qRT-PCR       Frozen                Lower than the median expression level              35                        16/19                            OS        Multivariate           3.42 (1.33--9.37)   Reported
  Lan et al[@b34-ott-9-5771]          2015   qRT-PCR       FFPE                  Lower than the median level of 1.60                 57                        30/27                            OS        Univariate             0.74 (0.37--1.44)   Survival curve
  Fujiwara et al[@b28-ott-9-5771]     2014   qRT-PCR       FFPE                  Lower than the optimal cutoff point                 48                        8/40                             OS        Univariate             0.25 (0.03--0.88)   Survival curve
  Chen et al[@b31-ott-9-5771]         2014   qRT-PCR       Frozen                Lower than the optimal cutoff value of 1.31         82                        36/46                            OS        Univariate             2.18 (1.33--3.73)   Survival curve
  Akanuma et al[@b32-ott-9-5771]      2014   qRT-PCR       FFPE                  Lower than the set of 0.012 (normalized to RNU6B)   84                        62/22                            OS        Univariate             1.98 (1.08--4.68)   Survival curve
  Wan et al[@b29-ott-9-5771]          2014   qRT-PCR       Frozen                Lower than the median value                         103                       52/51                            OS        Univariate             0.70 (0.33--1.42)   Survival curve
  Wang et al[@b26-ott-9-5771]         2014   qRT-PCR       Frozen                NSI                                                 112                       68/44                            OS        Multivariate           2.25 (1.13--4.29)   Reported
  Qin et al[@b27-ott-9-5771]          2013   qRT-PCR       Frozen                Lower than the median expression level              95                        47/48                            OS        Univariate             2.33 (1.77--4.30)   Survival curve
  Wang et al[@b25-ott-9-5771]         2014   qRT-PCR       Frozen                Low than the median level                           169                       84/85                            OS        Multivariate           1.70 (1.01--2.86)   Reported

**Abbreviations:** FFPE, formalin-fixed and paraffin-embedded; OS, overall survival; HR, hazard ratio; CI, confidence interval; NSI, no specific information; qRT-PCR, quantitative real-time polymerase chain reaction.

###### 

Main results of subgroup analyses

  Categories                   Subgroups                                                                                       References                                                                                      HR (95% CI)         *P*-value   Heterogeneity   
  ---------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------- ----------- --------------- -------
  All                          Total                                                                                           [@b24-ott-9-5771]--[@b29-ott-9-5771], [@b31-ott-9-5771]--[@b34-ott-9-5771]                      1.62 (1.16--2.24)   0.004       59.3            0.008
  Cancer type                  Osteosarcoma                                                                                    [@b24-ott-9-5771], [@b28-ott-9-5771], [@b33-ott-9-5771]                                         1.48 (0.51--4.29)   0.466       71.1            0.032
  Non-small-cell lung cancer   [@b26-ott-9-5771], [@b34-ott-9-5771]                                                            1.29 (0.43--3.84)                                                                               0.644               80.9        0.022           
  Digestive system neoplasms   [@b25-ott-9-5771], [@b27-ott-9-5771], [@b29-ott-9-5771], [@b31-ott-9-5771], [@b32-ott-9-5771]   1.73 (1.20--2.51)                                                                               0.003               52.2        0.079           
  Region                       East Asia                                                                                       [@b25-ott-9-5771]--[@b29-ott-9-5771], [@b31-ott-9-5771]--[@b34-ott-9-5771]                      1.53 (1.09--2.14)   0.013       60.3            0.010
  West Asia                    [@b24-ott-9-5771]                                                                               3.42 (1.29--9.08)                                                                               0.014               --          --              
  Tissue                       Frozen                                                                                          [@b24-ott-9-5771]--[@b27-ott-9-5771], [@b29-ott-9-5771], [@b31-ott-9-5771], [@b33-ott-9-5771]   1.89 (1.41--2.53)   \<0.001     40.5            0.121
  preservation                 FFPE                                                                                            [@b28-ott-9-5771], [@b32-ott-9-5771], [@b34-ott-9-5771]                                         0.88 (0.33--2.32)   0.791       70.0            0.036
  Analysis of variance         Univariate                                                                                      [@b27-ott-9-5771]--[@b29-ott-9-5771], [@b31-ott-9-5771]--[@b34-ott-9-5771]                      1.38 (0.88--2.15)   0.156       68.9            0.004
  Multivariate                 [@b24-ott-9-5771]--[@b26-ott-9-5771]                                                            2.07 (1.42--3.02)                                                                               \<0.001             0.0         0.443           

**Note:** "--" indicates no data.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; FFPE, formalin-fixed and paraffin-embedded.

###### 

The validated target genes of miR-133a in the eligible studies in this meta-analysis

  Study                             Year   Type of cancer               Validated target genes
  --------------------------------- ------ ---------------------------- -------------------------------
  Ji et al[@b33-ott-9-5771]         2013   Osteosarcoma                 Bcl-xL and Mcl-1
  Fujiwara et al[@b28-ott-9-5771]   2014   Osteosarcoma                 SGMS2, UBA2, SNX30, and ANXA2
  Akanuma et al[@b32-ott-9-5771]    2014   Esophageal cancer            FSCN1 and MMP14
  Wan et al[@b29-ott-9-5771]        2014   Colorectal cancer            LASP1, CAV1, and FSCN1
  Wang et al[@b26-ott-9-5771]       2014   Non-small-cell lung cancer   IGF-1R, TGFBR1, and EGFR
  Qin et al[@b27-ott-9-5771]        2013   Pancreatic cancer            FSCN1

**Abbreviations:** ANXA2, annexin A2; Bcl-xL, B-cell lymphoma-extra large; CAV1, caveolin-1; EGFR, epidermal growth factor receptor; FSCN1, Fascin-1; IGF-1R, insulin-like growth factor 1 receptor; LASP1, LIM and SH3 domain protein 1; MMP14, matrix metalloprotease 14; Mcl-1, myeloid cell leukemia-1; SGMS2, sphingomyelin synthase 2; SNX30, sorting nexin family member 30; TGFBR1, TGF-beta receptor type-1; UBA2, ubiquitin-like modifier activating enzyme 2.
